EGFR and neoplasm: Furthermore, EGFR was identified to be directly targeted by miR-27a, which restrained the activation of NF-κB via directly targeting EGFR, which indicates that miR-27a may act as a tumor suppressor through NF-κB pathway (Figure 6).